● enVVeno reported second-quarter 2026 financial results and advances toward an FDA pivotal trial for its first-in-class replacement venous valve.
Phreesia (NYSE:PHR), a healthcare-technology company that helps medical practices manage patient intake, scheduling and payments, has reached an important milestone: profitability. After years of prioritizing growth, the company crossed into positiveNet Incomewhile continuing to expand revenue.
ADC Therapeutics (NYSE:ADCT) is working to build on its approved lymphoma treatment while advancing a pipeline of antibody-drug conjugates. The company reported second-quarter 2026 results that narrowed its loss, though questions around a key confirmatory study tempered the picture.
Atossa Therapeutics (NASDAQ:ATOS) is advancing a differentiated approach to breast-cancer treatment and prevention. The company is building a body of evidence for its lead candidate across multiple settings, with the path forward running through clinical data and regulatory progress.
●Pediatric designation plans:On June 18, 2026, Cadrenal announced plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease.
● The company's lead drug simufilam failed to demonstrate benefit in Alzheimer's disease trials.
Karl G. Glassman, President and CEO of Leggett & Platt Inc., filed a Form 4 on August 27, 2026, disclosing multiple changes in beneficial ownership of common stock and derivative securities resulting from the company's merger with Somnigroup International Inc.
James Tyson Hagale, Executive Vice President and President of Bedding Products at Leggett & Platt Inc (NYSE:LEG), filed a Form 4 on August 27, 2026, reporting changes in beneficial ownership resulting from the company's merger with Somnigroup International Inc.
Ryan Michael Kleiboeker, EVP and Chief Strategic Planning Officer of Leggett & Platt Inc, filed a Form 4 on August 27, 2026, disclosing multiple changes in beneficial ownership resulting from the company's merger with Somnigroup International Inc., effective August 26, 2026.
Carlos G. Linares, EVP Chief Tech & Global New Product Officer at Church & Dwight Co Inc /DE/ (NYSE:CHD), filed a Form 4 on August 27, 2026, reporting the exercise of stock options and a same-day sale of common stock on August 26, 2026.